scholarly journals The analysis to the latest changes in NCCN Guidelines of Central Nervous System Cancers about low-grade gliomas and glioblastoma

2015 ◽  
Vol 1 (1) ◽  
Author(s):  
Tianyu Wang ◽  
Xiong Xiao ◽  
Nan Ji
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Low Grade ◽  
Nccn Guidelines ◽  
Low Grade Gliomas ◽  
Central Nervous System Cancers

Current View on Management of Central Nervous System Low-grade Gliomas

2016 ◽  
Vol 79/112 (5) ◽  
pp. 534-540
Author(s):  
Jiří Polívka ◽  
Jiří Polívka ◽  
Vladimír Rohan ◽  
V. Přibáň
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Current View ◽  
Low Grade ◽  
Low Grade Gliomas

scholarly journals NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017

2017 ◽  
Vol 15 (11) ◽  
pp. 1331-1345 ◽  
Author(s):  
Louis Burt Nabors ◽  
Jana Portnow ◽  
Mario Ammirati ◽  
Joachim Baehring ◽  
Henry Brem ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Nccn Guidelines ◽  
Central Nervous System Cancers

scholarly journals Oncology is changing: the challenge of effectively assessing response within clinical trials in low-grade gliomas

2011 ◽  
pp. 75-76
Author(s):  
Ilaria Imarisio ◽  
Chiara Fumagalli
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Who Classification ◽  
Low Grade ◽  
High Grade ◽  
Low Grade Gliomas ◽  
Microvascular Proliferation ◽  
Grade Iii

The current WHO classification of primary central nervous system (CNS) tumors recognizes four separate tumor grades (I–IV), which can be grouped into low-grade (I and II) or high-grade (III and IV), depending on the absence or presence of high-grade histopathological features, such as microvascular proliferation and necrosis...

Oncology is changing: the challenge of effectively assessing response within clinical trials in low-grade gliomas

2011 ◽  
Vol 5 (2) ◽  
pp. 75
Author(s):  
Ilaria Imarisio ◽  
Chiara Fumagalli
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Who Classification ◽  
Low Grade ◽  
High Grade ◽  
Low Grade Gliomas ◽  
Microvascular Proliferation ◽  
Grade Iii

The current WHO classification of primary central nervous system (CNS) tumors recognizes four separate tumor grades (I–IV), which can be grouped into low-grade (I and II) or high-grade (III and IV), depending on the absence or presence of high-grade histopathological features, such as microvascular proliferation and necrosis...

scholarly journals Original article Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system

2013 ◽  
Vol 1 ◽  
pp. 26-32 ◽  
Author(s):  
Daniel Ręcławowicz ◽  
Mirosław Stempniewicz ◽  
Wojciech Biernat ◽  
Janusz Limon ◽  
Paweł Słoniewski
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Genetic Material ◽  
Low Grade ◽  
Low Grade Gliomas

scholarly journals Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

2020 ◽  
Vol 18 (11) ◽  
pp. 1537-1570
Author(s):  
Louis Burt Nabors ◽  
Jana Portnow ◽  
Manmeet Ahluwalia ◽  
Joachim Baehring ◽  
Henry Brem ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Interdisciplinary Team ◽  
Intracranial Tumors ◽  
Who Grade ◽  
Nccn Guidelines ◽  
Pilocytic Astrocytomas ◽  
Key Factor ◽  
Central Nervous System Cancers

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and neuroradiologists, is a key factor in the appropriate management of CNS cancers. Integrated histopathologic and molecular characterization of brain tumors such as gliomas should be standard practice. This article describes NCCN Guidelines recommendations for WHO grade I, II, III, and IV gliomas. Treatment of brain metastases, the most common intracranial tumors in adults, is also described.

scholarly journals Perfusion and permeability MRI in glioma grading

2020 ◽  
Vol 51 (1) ◽  
Author(s):  
Sonay Aydin ◽  
Erdem Fatihoğlu ◽  
Pınar Nercis Koşar ◽  
Elif Ergün
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Sensitivity And Specificity ◽  
Perfusion Mri ◽  
Low Grade ◽  
High Grade ◽  
Brain Glioma ◽  
Grade Group ◽  
Low Grade Gliomas ◽  
The Central Nervous System

Abstract Background MRI is successful in showing the anatomy of probable pathologies of the central nervous system. Although it may not be sufficient to reveal physiological and metabolic changes, advanced MRI techniques, such as perfusion and permeability MRI, are the key to overcoming these limitations. The aim of this study was to detect the efficacy of permeability and perfusion MRI techniques. Results The study included 38 patients with a pathology result of primary brain glioma. The permeability MRI (Ktrans, Ve), perfusion MRI values (CBV, CBF), and pathology results were evaluated. The high-grade group included 22 patients, and the low-grade group, 16 patients. Mean CBV and CBF, median Ktrans, and Ve values were higher in the high-grade group. All parameters tended to elevate with grade and had a positive correlation. CBV > 2.25, with sensitivity and specificity of 100%, CBF > 2.02, with sensitivity and specificity of 100%, Ktrans > 0.043, with sensitivity of 81.82% and specificity of 100%, and Ve > 0.255, with sensitivity and specificity of 100%, can predict high grade. Conclusion Perfusion and permeability MRI can be used safely for the differentiation of high- and low-grade gliomas and for the prediction of glioma grades.

scholarly journals QOL-36. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii438-iii438
Author(s):  
Kathleen Dorris ◽  
Jessica Channell ◽  
Ashley Mettetal ◽  
Molly Hemenway ◽  
Natalie Briones ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Central Nervous System ◽  
Nervous System ◽  
Cell Activity ◽  
Cns Tumors ◽  
Low Grade ◽  
Tumor Type ◽  
Central Nervous System Tumor ◽  
The Impact

Abstract BACKGROUND Cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), are a class of compounds found in marijuana. Numerous studies in adults have examined cannabinoid use in management of cancer-related symptoms such as nausea, anorexia, and pain. Less is known about the use in the pediatric oncology population. METHODS A prospective observational study has been ongoing since 2016 at Children’s Hospital Colorado to evaluate cannabinoids’ impact using PedsQL™ modules on quality of life of pediatric patients with central nervous system (CNS) tumors who are 2–18 years old. Laboratory assessments of T-cell activity and pharmacokinetics of CBD, THC and associated metabolites are in process. Diaries with exploratory information on cannabinoid use patterns are being collected. RESULTS Thirty-three patients (14:19; male:female) have been enrolled with a median age of 6.4 years (range, 2.9–17.7 years). The most common tumor type in enrolled patients is embryonal tumors (13/33; 39%). Nine (27%) patients have low-grade glial/glioneuronal tumors, and eight (24%) had high-grade/diffuse midline gliomas. The remaining patients had ependymoma or craniopharyngioma. The median time on cannabinoids is 9 months. Most (n=20) patients have used oral products with CBD and THC. One patient continues on cannabinoid therapy in follow up. Preliminary immune function analyses identified impaired neutrophil superoxide anion production and chemotaxis in patients taking cannabinoids at early time points on therapy. CONCLUSIONS Families of children with various CNS tumors are pursuing cannabinoid therapy for both antitumor and supportive care purposes. Analysis of the impact of cannabinoids on patients’ quality of life is ongoing.

Sign in / Sign up

Export Citation Format

Share Document